A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | MicrobiomeTrials
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-10-10Est. Completion: 2028-04-01
Enrollment target: 98 participants
Locations
Valkyrie Clinical Trials, Los Angeles, California, United States
SCRI HealthOne, Denver, Colorado, United States
Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
University of Chicago, Chicago, Illinois, United States
NYU Langone Health, New York, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Oklahoma University, Oklahoma City, Oklahoma, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
Texas Oncology- Central South, Austin, Texas, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Texas Oncology- Gulf Coast, The Woodlands, Texas, United States
Virginica Cancer Specialists, Fairfax, Virginia, United States
Other microbiome trials you might be interested in